Lexapro

(Escitalopram)

ApprovedSmall molecule

Escitalopram is used to treat depression and anxiety disorders by helping to balance chemicals in the brain that affect mood and emotions.[2] Lexapro is currently approved and in use across 48 indications[4].[1]

Lexapro is one of 806 small molecule programs targeting Hepatitis C Virus Infection. It is currently in Approved.

Indications

326

Total Trials

Active Trials

805

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[4][1]

Indication

Hepatitis C Virus InfectionApproved

Depressive DisorderApproved

Gastrointestinal DiseaseApproved

Drug DependenceApproved

Dissociative DisorderActive, not recruiting

EpilepsyWithdrawn

Prurigo NodularisActive, not recruiting

Morbid ObesityActive, not recruiting

Cannabis DependenceActive, not recruiting

Irritable Bowel Syndrome With ConstipationRecruiting

Hepatitis C Virus InfectionApproved

Approved

Depressive DisorderApproved

Approved

Gastrointestinal DiseaseApproved

Approved

Drug DependenceApproved

Approved

Dissociative DisorderPreclinical

Active, not recruiting

EpilepsyApproved

Withdrawn

Prurigo NodularisPreclinical

Active, not recruiting

Morbid ObesityPreclinical

Active, not recruiting

Cannabis DependencePreclinical

Active, not recruiting

Irritable Bowel Syndrome With ConstipationPreclinical

Recruiting

Showing 10 of 46 indications

Competition

Competitive Landscape

174 competitors in Schizophrenia

#DrugCompanyPhaseTrials

Lexapro

AbbVie

Approved

3 2

Ozempic

Novo Nordisk

Preclinical

1 3

Resotran

Takeda

Preclinical

1 4

Inapsine

Jazz Pharmaceuticals

Preclinical

1 5

Depakote

Ibrance

Lunesta

3 8

Luvox

SSolvay Pharmaceuticals

Preclinical

1 9

Catapres

Boehringer Ingelheim

Preclinical

1 10

Rapamune

PPrism Pharmaceuticals

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Recruiting

Bariatric Surgery

NCT03460379

Phase 2Recruiting

Efficacy and Safety

NCT06828887

Q4 2027

Post-ApprovalRecruiting

Treatment

NCT07478796

Post-ApprovalActive, not recruiting

Humans

NCT04336228

Q2 2028

Phase 3Recruiting

Major Depressive Disorder

NCT05603104

Phase 3Recruiting

First-Line Treatment

NCT05973786

Clinical

Trials by Indication[1]

Major Depressive Disorder35 trials

Study of Escitalopram in Adult Patients With Major Depressive Disorder

Completed·FForest Laboratories·Phase 3·NCT00108979·240 enrolled

To Assess the Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)

Terminated· Otsuka logo

Otsuka·Phase 3·NCT01123707·173 enrolled

Effects of Escitalopram on the Sleep EEG Power in Patients With Major Depressive Disorder

Completed·PPeking University Sixth Hospital·N/A·NCT04013464·31 enrolled

Show 32 more trials

Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)

Terminated· Otsuka logo

Otsuka·Phase 3·NCT01111539·211 enrolled

The Safety and Efficacy of Escitalopram in Pediatric Patients With Major Depressive Disorder

Completed·FForest Laboratories·Phase 3·NCT00107120·312 enrolled

An Eight-week Study of Saredutant and Escitalopram as Combination Treatment for Major Depressive Disorder

Completed· Sanofi logo

Sanofi·Phase 3·NCT00531622·643 enrolled

A Comparative Study of Sage-217 Plus an Antidepressant (ADT) Versus Placebo Plus an ADT in Adults With Major Depressive Disorder

Completed· Biogen logo

Biogen·Phase 3·NCT04476030·440 enrolled

A Study to Evaluate the Impact of Escitalopram on Quality of Life and Social Functionality in Patients With Major Depressive Disorder With Anxiety Symptom

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 4·NCT01870843·261 enrolled

Safety Study of Escitalopram in Children 7 to 11 Years of Age With Major Depressive Disorder

Completed·FForest Laboratories·Phase 4·NCT01198795·162 enrolled

A Comparative Study on Efficacy and Safety of add-on Sulforaphane or rTMS to Escitalopram for Major Depressive Disorder With Poor Response to Initial Treatment

Unknown status·SShanghai Mental Health Center·Phase 4·NCT05145270·180 enrolled

Efficacy and Safety Study of ABT-436 in Major Depressive Disorder

Terminated· AbbVie logo

AbbVie·Phase 2·NCT01741142·19 enrolled

Treatment of Outpatients With Severe Asthma and Moderate or Severe Major Depressive Disorder

Completed·UUniversity of Texas Southwestern Medical Center·Phase 4·NCT00621946·26 enrolled

Cardiovascular Effects of Agomelatine and Escitalopram in Patients With Major Depressive Disorder (MDD)

Unknown status·BBaker Heart and Diabetes Institute·Phase 4·NCT01483053·40 enrolled

An Eight-week Study Evaluating the Efficacy of a 100mg Dose of Saredutant Once Daily, in Elderly Patients With Major Depressive Disorder

Completed· Sanofi logo

Sanofi·Phase 3·NCT00415142·393 enrolled

Efficacy of Seroquel SR in Combination With an Antidepressant in Treatment of Major Depressive Disorder

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT00351910·494 enrolled

An Efficacy and Safety Study of Escitalopram Long-Term Treatment in Major Depressive Disorder With Associated Anxiety Symptoms

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 4·NCT01814098·318 enrolled

Vortioxetine (Lu AA21004) 10 and 20 mg for Treatment of Major Depressive Disorder With Sexual Dysfunction

Completed· Takeda logo

Takeda·Phase 3·NCT01364649·447 enrolled

Brain Energy Metabolism in Individuals With Major Depressive Disorder Receiving Escitalopram

Completed·MMassachusetts General Hospital·Phase 4·NCT00183677·97 enrolled

Neuroimaging Study of Bupropion Treatment in Patients With Major Depressive Disorder

Completed·EEwha Womans University·Phase 4·NCT01541475·60 enrolled

Study of BMS-562086 in the Treatment of Outpatients With Major Depressive Disorder

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1/2·NCT00135421·271 enrolled

Treatment Outcome in Major Depressive Disorder

Completed·RRigshospitalet, Denmark·Phase 1·NCT02869035·100 enrolled

Effect of Escitalopram vs. Reboxetine on Gastro-intestinal Sensitivity of Patients With Major Depressive Disorder

Unknown status·HHospital Universitari Vall d'Hebron Research Institute·Phase 4·NCT00209807·42 enrolled

Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression After a First-time Treatment Failure

Recruiting·—·Phase 3·NCT05603104·1,254 enrolled

Eszopiclone Co-Administered With Escitalopram for Insomnia in Elderly Adults With Major Depressive Disorder

Completed·LLehigh Center for Clinical Research·Phase 4·NCT00813735·60 enrolled

Effect of Antidepressants on the Treatment for Korean Major Depressive Disorder Patients

Terminated·MMinistry of Health & Welfare, Korea·Phase 4·NCT00926835·692 enrolled

Escitalopram in the Treatment of Adolescents With Major Depressive Disorder or Anxiety Disorders

Unknown status·—·Phase 4·NCT03122158·60 enrolled

Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)

Terminated· Otsuka logo

Otsuka·Phase 3·NCT01111552·237 enrolled

Study on the Effect of PRKCB1 Modulating Inflammatory Factors and the Role for Developing Major Depressive Disorder

Unknown status·SShanghai Mental Health Center·N/A·NCT03899194·350 enrolled

A Trial Evaluating the Efficacy and Tolerability of SSR125543 in Outpatients With Major Depressive Disorder

Completed· Sanofi logo

Sanofi·Phase 2·NCT01034995·580 enrolled

Algorithm Guided Treatment Strategies for Major Depressive Disorder

Unknown status·SShanghai Mental Health Center·Phase 4·NCT01764867·1,080 enrolled

Electrophysiologic Parameters and Biomarkers Predicting Treatment Response in Patients With Major Depressive Disorder

Unknown status·SSeoul National University Bundang Hospital·Phase 4·NCT01997580·600 enrolled

Efficacy of Seroquel SR in Combination With an Antidepressant in Treatment of Major Depressive Disorder

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT00351169·450 enrolled

Study on the Optimal Diagnosis and Treatment Strategy of Major Depressive Disorder Based on Anhedonia

Unknown status·PPeking University·N/A·NCT05389046·252 enrolled

Neurobiological Bases of Placebo Response in Major Depressive Disorder

Terminated·MMassachusetts General Hospital·Phase 4·NCT01787240·20 enrolled

Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder (the Orion Trial)

Completed· Otsuka logo

Otsuka·Phase 3·NCT01360866·2,944 enrolled

Depression22 trials

Efficacy Study of Escitalopram for Depression in Patients With Diabetes

Unknown status·SSheba Medical Center·Phase 4·NCT00650897·30 enrolled

Antidepressant Medication Plus Donepezil for Treating Late-life Depression

Completed·UUniversity of Pittsburgh·Phase 4·NCT00177671·220 enrolled

Augmenting Antidepressant Treatment With Interpersonal Psychotherapy for Treating Late-life Depression

Completed·UUniversity of Pittsburgh·Phase 4·NCT00177294·319 enrolled

Show 19 more trials

Acamprosate Added to Escitalopram and Behavioral Treatment for Comorbid Depression and Alcoholism

Completed·MMassachusetts General Hospital·Phase 4·NCT00452543·23 enrolled

Emotional and Cognitive Control in Late-Onset Depression

Completed·WWeill Medical College of Cornell University·Phase 4·NCT01728194·121 enrolled

Neurotrophic Factors and Depression

Completed·UUniversity of California, San Francisco·Phase 4·NCT00812994·30 enrolled

Depression-Diabetes Mechanisms: Urban African Americans

Completed·EEmory University·Phase 4·NCT00209170·20 enrolled

Investigation of Tibolone and Escitalopram in Perimenopausal Depression

Terminated·TThe Alfred·Phase 4·NCT01368068·2 enrolled

Promoting Enhanced Pharmacotherapy Choice Through Immunomarkers Evaluation in Depression

Terminated·UUniversity of Texas Southwestern Medical Center·Phase 4·NCT03993457·18 enrolled

Canadian Biomarker Integration Network for Depression Study

Completed·UUniversity Health Network, Toronto·Phase 3·NCT01655706·211 enrolled

Canadian Biomarker Integration Network for Depression (CAN-BIND) - Validation Study

Completed·UUniversity Health Network, Toronto·Phase 3·NCT04162522·1 enrolled

Treatment of Depression in Adults

Completed·UUniversity of Pittsburgh·Phase 4·NCT00073697·290 enrolled

Dichotic Listening as a Predictor of Medication Response in Depression

Completed·NNew York State Psychiatric Institute·Phase 4·NCT00404755·17 enrolled

Determining Optimal Treatment Sequences in Anxious Depression (DOTS-AD)

Recruiting·UUniversity of Cincinnati·Phase 4·NCT04245748·84 enrolled

Personalized Escitalopram Dosing in Patients With Depression

Unknown status·UUniversity of Belgrade··NCT05210140·148 enrolled

A Diagnosis and Treatment Optimization Study of Depression Based on the Neurological Mechanism of Reward System

Unknown status·PPeking University·N/A·NCT03148522·120 enrolled

SSRI Effects on Depression and Immunity in HIV/AIDS

Completed·UUniversity of Pennsylvania·Phase 4·NCT02620150·108 enrolled

Treatment of Depression in the Elderly

Terminated·—·Phase 4·NCT00130455·189 enrolled

Treatment of Depression Following Multiple Brain Tests

Completed·NNew York State Psychiatric Institute·Phase 4·NCT00296777·28 enrolled

Exploring Biomarkers for Depression

Completed·—··NCT01424111·51 enrolled

Quantitative Electroencephalogram (QEEG) Predictors of Response to Psychotherapy Versus Antidepressant Treatment in Depression

Completed·MMassachusetts General Hospital·Phase 4·NCT00824044·39 enrolled

Duloxetine Compared to Escitalopram and Placebo in the Treatment of Patients With Depression

Completed· Eli Lilly logo

Eli Lilly·Phase 3·NCT00073411·675 enrolled

Treatment Resistant Depression8 trials

A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT02422186·139 enrolled

A Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT02418585·236 enrolled

A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT02493868·719 enrolled

Show 5 more trials

Investigate the Clinical Responses of Ethosuximide in Patients With Treatment-Resistant Depression.

Completed·ZZhejiang University·Phase 1·NCT03887624·16 enrolled

Interpersonal Psychotherapy for Treatment Resistant Depression

Unknown status·HHospital de Clinicas de Porto Alegre·N/A·NCT01896349·74 enrolled

A Study of Esketamine Nasal Spray Plus a New Standard-of-care Oral Antidepressant or Placebo Nasal Spray Plus a New Standard-of-care Oral Antidepressant in Adult and Elderly Participants With Treatment-resistant Depression

Withdrawn· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT03852160

Dopaminergic Effects of Adjunctive Aripiprazole on the Brain in Treatment-Resistant Depression

Completed·WWashington University School of Medicine·N/A·NCT00953745·43 enrolled

A Naturalistic Study of the Efficacy and Safety of Escitalopram in Treatment Resistant Depression

Unknown status·SSheba Medical Center·N/A·NCT00220480·60 enrolled

Generalized Anxiety Disorder7 trials

A Study of Escitalopram in the Treatment of Children and Adolescents With Generalized Anxiety Disorder

Completed· AbbVie logo

AbbVie·Phase 4·NCT03924323·273 enrolled

Escitalopram in Patients With Generalized Anxiety Disorder

Completed· Lundbeck logo

Lundbeck·Phase 4·NCT00902564·30 enrolled

Drug Therapy for Generalized Anxiety Disorder Among the Elderly

Completed·UUniversity of Pittsburgh·Phase 4·NCT00105586·177 enrolled

Show 4 more trials

Study of Pexacerfont (BMS-562086) in the Treatment of Outpatients With Generalized Anxiety Disorder

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2/3·NCT00481325·260 enrolled

Cognitive-Behavioral Therapy and Escitalopram for Generalized Anxiety Disorder(GAD)

Completed·NNew York State Psychiatric Institute·Phase 4·NCT00219349·25 enrolled

ERP N1 as a Treatment Predictor of Generalized Anxiety Disorder

Completed·IInje University·N/A·NCT00613067·35 enrolled

An Eight-week Study to Evaluate the Efficacy and Safety of Saredutant in Patients With Generalized Anxiety Disorder

Completed· Sanofi logo

Sanofi·Phase 3·NCT00417118·365 enrolled

Treatment6 trials

Escitalopram Treatment of Night Eating Syndrome

Completed·—·N/A·NCT00636649·40 enrolled

Efficacy of Escitalopram in the Treatment of Internet Addiction

Completed·IIcahn School of Medicine at Mount Sinai·Phase 4·NCT00565422·31 enrolled

Treatment Choices for Improving Adherence and Outcome

Completed·WWeill Medical College of Cornell University·N/A·NCT00194948·60 enrolled

Show 3 more trials

TDM-Guided Treatment With SSRIs in Hospitalized Adults and Children

Recruiting·PPoznan University of Medical Sciences·Phase 4·NCT07478796·180 enrolled

Investigation of a Combination Treatment of Escitalopram and rTMS

Completed·—·N/A·NCT00232700·42 enrolled

Investigation of Genetic Predictors of the Response to Selective Serotonin Re-uptake Inhibitors (SSRI) Treatment

Completed·UUniversity of Tartu·Phase 4·NCT03927950·135 enrolled

79 more indications

Major Depression6 trials

Safety and Effectiveness of S-adenosyl-l-methionine (SAMe) for the Treatment of Major Depression

Completed·—·N/A·NCT00101452·199 enrolled

Lexapro and Pramipexole and to Treat Major Depression

Completed·NNational Institute of Mental Health (NIMH)·Phase 2·NCT00086307·39 enrolled

Escitalopram (Lexapro®) In Patients With Major Depression With Atypical Features

Completed·—·Phase 3·NCT00610506·15 enrolled

Show 3 more trials

A Study for Participants With Major Depression

Completed· Eli Lilly logo

Eli Lilly·Phase 2·NCT00420004·469 enrolled

Personalized Indicators for Predicting Response to SSRI Treatment in Major Depression (The PRISE-MD Study)

Completed·UUniversity of California, Los Angeles·Phase 4·NCT00917059·172 enrolled

Optimized Predictive Treatment In Medications for Unipolar Major Depression (OPTIMUM-D)

Recruiting·NNova Scotia Health Authority·Phase 4·NCT05017311·400 enrolled

Obsessive-Compulsive Disorder5 trials

Treatment Youth With Obsessive-Compulsive Disorder

Unknown status·UUniversity of Ottawa·Phase 4·NCT00708240·40 enrolled

Pilot Study to Evaluate Escitalopram in Obsessive-compulsive Disorder

Completed·—·Phase 2·NCT00215137·14 enrolled

Comparison of Effects Between Conventional Dose and High Dose Escitalopram on Clinical Improvement in Patients With Obsessive-compulsive Disorder

Completed·SSeoul National University Hospital·Phase 4·NCT00723060·176 enrolled

Show 2 more trials

Predicting Medication Response in Obsessive Compulsive Disorder

Completed·SSunnybrook Health Sciences Centre·N/A·NCT01404871·26 enrolled

Tolerability and Efficacy of High Dose Escitalopram for the Treatment of Obsessive-Compulsive Disorder (OCD)

Completed·—·Phase 3·NCT00305500·100 enrolled

ESS5 trials

Serotonin Transporter Genetic Variation and Amygdalar Activation Correlates of Antidepressant Response

Completed·IIndiana University School of Medicine·Phase 4·NCT00456430·80 enrolled

Connectivity Affecting the Antidepressant REsponse Study

Completed·VVanderbilt University Medical Center·Phase 4·NCT02332291·95 enrolled

Study of Neural Responses Induced by Antidepressant Effects

Completed·MMarta Peciña, MD PhD·Phase 2/3·NCT02674529·60 enrolled

Show 2 more trials

Does Dual Therapy Hasten Antidepressant Response?

Completed·NNew York State Psychiatric Institute·Phase 4·NCT00519428·245 enrolled

The Effects of Increased Central Serotonergic Activity on Information Processing

Completed·UUniversity of Copenhagen·N/A·NCT00206934·40 enrolled

Stroke4 trials

Preventing Post-Stroke Depression

Completed·—·N/A·NCT00071643·201 enrolled

Effects on Clinical and Functional Outcome of Escitalopram in Adult Stroke Patients

Unknown status·AAzienda Ospedaliero Universitaria Maggiore della Carita·Phase 4·NCT00967408·200 enrolled

The Preventive Effect of Escitalopram on Depression and Related Emotional Disorders in Acute Stroke Patients

Unknown status·—·Phase 4·NCT01278498·444 enrolled

Show 1 more trial

Escitalopram Treatment In Acute Stroke

Withdrawn·UUniversity of Aarhus·Phase 4·NCT01561092

Alzheimer's Disease3 trials

Progression Delaying Effect of Escitalopram in Alzheimer's Disease

Completed·SSeoul National University Hospital·N/A·NCT00702780·74 enrolled

Escitalopram for the Treatment of Depression in Alzheimer's Disease

Completed·KKonkuk University Medical Center·Phase 4·NCT01841125·84 enrolled

Escitalopram Treatment for BPSD in Alzheimer's Disease in Comparison to Risperidone

Completed·—·Phase 4·NCT01119638·40 enrolled

Medication3 trials

Optimizing Antidepressant Treatment by Genotype-dependent Adjustment of Medication According to the ABCB1 Gene

Unknown status·HHolsboerMaschmeyer NeuroChemie GmbH·Phase 4·NCT02237937·80 enrolled

Brain Activity Changes and Treatment Response in Depressed People Who Are Receiving Antidepressant Medication

Completed·NNational Institute of Mental Health (NIMH)·Phase 4·NCT00375843·118 enrolled

Wearable Devices to Assess Effects of Central Nervous Medications on Physical Conditions in Patients With Sleep Problems

Completed·TTri-Service General Hospital··NCT05300386·52 enrolled

Antidepressants3 trials

Are Two Antidepressants a Good Initial Treatment for Depression?

Completed·NNew York State Psychiatric Institute·Phase 4·NCT00296712·55 enrolled

A Neuroimaging and Epigenetic Investigation of Antidepressants in Depression

Completed·KKunming Medical University·N/A·NCT00703742·200 enrolled

TMC435-TiDP16-C112 - Interaction Trial With Antidepressants

Completed· Tibotec Pharmaceuticals, Ireland logo

Tibotec Pharmaceuticals, Ireland·Phase 1·NCT01090700·20 enrolled

Insomnia3 trials

Behavioral Insomnia Therapy For Those With Insomnia and Depression

Unknown status·TToronto Metropolitan University·N/A·NCT00620789·477 enrolled

Characteristics of Sleep Patterns in Young Adults With and Without Insomnia

Completed·UUniversity of Pittsburgh·Phase 4·NCT00177216·69 enrolled

Brain Mechanisms and Targeting Insomnia in Major Depression

Unknown status·UUniversity of California, Los Angeles·Phase 4·NCT00628914·60 enrolled

Borderline personality disorder2 trials

Selective Serotonin Reuptake Inhibitors (SSRIs) in Borderline Personality Disorder

Terminated·UUniversity of Chicago·Phase 2·NCT01103180·70 enrolled

DBT and Escitalopram in Borderline Personality Disorder

Unknown status·—·N/A·NCT00255554

Head and Neck Cancer2 trials

Evaluating the Effectiveness of Escitalopram to Prevent Depression in Head and Neck Cancer Patients Receiving Treatment

Completed·UUniversity of Nebraska·Phase 4·NCT00536172·160 enrolled

Double-blind, Placebo-controlled, Randomized Study of the Effectiveness of Escitalopram on Emotional Distress of Head and Neck Cancer Patients During Cancer Treatment

Unknown status·GGustave Roussy, Cancer Campus, Grand Paris·Phase 3·NCT00935675·100 enrolled

Postpartum Depression2 trials

Escitalopram (Lexapro) for the Treatment of Postpartum Depression

Completed·MMassachusetts General Hospital·Phase 4·NCT00833469·7 enrolled

Escitalopram in the Treatment of Postpartum Depression

Completed·—·N/A·NCT01527474·20 enrolled

Hepatitis C2 trials

Efficacy and Safety of Escitalopram for Prevention of Depression Induced by Peg-Interferon in Hepatitis C Patients

Completed·GGermans Trias i Pujol Hospital·Phase 2·NCT00166296·133 enrolled

Escitalopram for the Prevention of PEGASYS-associated Depression in Hepatitis C Virus-infected Patients

Completed·—·Phase 3·NCT00136318·208 enrolled

Prevention2 trials

PTSD Prevention Using Escitalopram

Completed·SSheba Medical Center·N/A·NCT00300313·450 enrolled

Relapse Prevention With Escitalopram or Nortriptyline Following Electro-Convulsive Treatment (DUAG-7)

Terminated·HHillerod Hospital, Denmark·Phase 4·NCT00660062·47 enrolled

Post-Traumatic Stress Disorder2 trials

Open Trial of Escitalopram Treatment for Male Subjects With Posttraumatic Stress Disorder

Completed·NNorthern California Institute of Research and Education·N/A·NCT01024140·16 enrolled

Treatment of Post-traumatic Stress Disorder With High Doses of Escitalopram

Completed·HHadassah Medical Organization·N/A·NCT00736021·38 enrolled

Efficacy and Safety2 trials

Dose-Finding Clinical Trial to Evaluate the Efficacy and Safety of LV232 Capsules in the Treatment of MDD

Recruiting·VVigonvita Life Sciences·Phase 2·NCT06828887·400 enrolled

Efficacy and Safety of Escitalopram Doses up to 50mg in Treatment of MDD

Completed·CCommunity Pharmacology Services Ltd·Phase 4·NCT00785434·60 enrolled

Schizophrenia2 trials

Escitalopram in Schizophrenia in OCD- Open Label Study

Completed·—·Phase 4·NCT00456937·15 enrolled

Efficacy and Safety Study of Escitalopram Augmentation in Treatment Resistant Schizophrenia

Completed·EEmory University·Phase 4·NCT00231335·30 enrolled

Clinical Trial2 trials

A Clinical Trial to Investigate the Pharmacokinetics and the Effect on ECG of Escitalopram in Elderly Volunteers

Completed·SSeoul National University Hospital·Phase 1·NCT02122939·12 enrolled

Establishment of Cessation Therapy by Clinical Trials for Subjects With Betel-quid Dependence and Oral Pre-cancer

Terminated·—·Phase 2·NCT03010761·90 enrolled

Anxiety2 trials

Neurofunctional Predictors of Escitalopram Treatment Response in Adolescents With Anxiety

Completed·UUniversity of Cincinnati·N/A·NCT02818751·84 enrolled

Effect of Attention Training or SSRIs on Symptoms and Neural Activation in Social Anxiety

Completed·TTel Aviv University·N/A·NCT03346239·105 enrolled

Severe Depression2 trials

A Safety and Effectiveness Study of JNJ-18038683 in Patients With Moderate to Severe Depression

Completed· Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logo

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 2·NCT00566202·67 enrolled

Mineralocorticoid Receptor in the Treatment of Severe Depression

Completed·UUniversitätsklinikum Hamburg-Eppendorf·N/A·NCT00295347·65 enrolled

Elective2 trials

Vortioxetine in the Elderly vs. Selective Serotonin Reuptake Inhibitors (SSRIs): a Pragmatic Assessment

Completed·AAzienda Ospedaliera Universitaria Integrata Verona·Phase 4·NCT03779789·362 enrolled

Enhancement of Learning Associated Neural Plasticity by Selective Serotonin Reuptake Inhibitors

Unknown status·MMedical University of Vienna·Phase 4·NCT02753738·80 enrolled

Dyspepsia2 trials

Functional Dyspepsia Treatment Trial

Completed·MMayo Clinic·Phase 2/3·NCT00248651·292 enrolled

SSRI Study for Functional Dyspepsia (SS)

Completed·—·Phase 3·NCT02153567·71 enrolled

Acute Coronary Syndrome1 trial

DECARD: Study of Escitalopram in the Prevention of Depression in Patients With Acute Coronary Syndrome

Unknown status·—·Phase 4·NCT00140257·240 enrolled

Anhedonia1 trial

Adjunctive Game Intervention for Anhedonia in MDD Patients

Completed·—·N/A·NCT04977232·50 enrolled

Adult1 trial

Antidepressant Response in Older Adults With Comorbid PTSD and MDD

Terminated·NNew York State Psychiatric Institute·Phase 4·NCT04697693·1 enrolled

Agitation1 trial

Escitalopram for Agitation in Alzheimer's Disease

Active, not recruiting·JJHSPH Center for Clinical Trials·Phase 3·NCT03108846·187 enrolled

Bariatric Surgery1 trial

Bariatric Surgery and Pharmacokinetics of Escitalopram

Recruiting·NNorwegian University of Science and Technology··NCT03460379·12 enrolled

Bipolar Depression1 trial

Cyclooxygenase-2-Inhibitor Combination Treatment for Bipolar Depression

Completed·LLoyola University·Phase 4·NCT01479829·100 enrolled

Executive Dysfunction1 trial

Aging Brain Changes, Executive Dysfunction and Depression

Completed·WWeill Medical College of Cornell University·Phase 4·NCT00918684·116 enrolled

Myocardial Ischemia1 trial

Responses of Myocardial Ischemia to Escitalopram Treatment

Completed·—·Phase 4·NCT00574847·127 enrolled

Chronic Obstructive Pulmonary Disease1 trial

Escitalopram in Anxiety Associated Chronic Obstructive Pulmonary Disease (COPD) Exacerbations

Withdrawn·HHull University Teaching Hospitals NHS Trust·Phase 3·NCT01522092

Glioblastoma1 trial

The Effect of Escitalopram on Mood, Quality of Life and Cognitive Functioning in Glioblastoma Patients

Unknown status·TTel-Aviv Sourasky Medical Center·Phase 2/3·NCT02623231·100 enrolled

Depressed1 trial

Fixed Dose Comparison of Escitalopram to an Active Comparator in Severely Depressed Patients

Completed·FForest Laboratories·Phase 4·NCT00384436·580 enrolled

Polyneuropathy1 trial

Escitalopram as a Treatment for Pain in Polyneuropathy

Completed·OOdense University Hospital·Phase 4·NCT00162968·50 enrolled

Safety and Efficacy1 trial

A Safety and Efficacy Study of Escitalopram on Acute Treatment of Severe Depression

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 4·NCT01814085·225 enrolled

Acute Stress Disorder1 trial

SSRI Administration to Reduce Acute Stress Disorder Symptoms and Prevent Depression and PTSD in Physical Trauma Victims

Terminated·MMassachusetts General Hospital·Phase 3·NCT00114374·60 enrolled

MPA1 trial

Impact of Escitalopram on Sperm DNA Fragmentation

Terminated·WWeill Medical College of Cornell University·Phase 2·NCT03527043·75 enrolled

Back pain1 trial

Cipralex in Treatment of Depressive Symptoms and Chronic Back Pain

Withdrawn·MMartin-Luther-Universität Halle-Wittenberg·Phase 4·NCT00227292

Psilocybin1 trial

Effects of SERT Inhibition on the Subjective Response to Psilocybin in Healthy Subjects

Completed·UUniversity Hospital, Basel, Switzerland·Phase 1·NCT03912974·27 enrolled

End-Stage Renal Disease1 trial

The Routine Use of SSRI's at the Initiation of End-stage Renal Disease Treatment (RoSIE)

Terminated·UUniversity Health Network, Toronto·Phase 2·NCT02407821·25 enrolled

Hot flashes1 trial

A Study Following Women in Menopause Treated With a Non-hormonal Therapy for Hot Flashes and Night Sweats

Active, not recruiting· Astellas logo

Astellas··NCT06049797·999 enrolled

Suicide1 trial

Treatment of Adolescent Suicide Attempters (TASA)

Completed·NNew York State Psychiatric Institute·Phase 2/3·NCT00080158·120 enrolled

Electroencephalography1 trial

Electroencephalography (EEG) Signal Processing

Unknown status·SSt. Joseph's Healthcare Hamilton··NCT01369290·150 enrolled

Magnetic Resonance Imaging1 trial

A Study of the Ability of Functional Magnetic Resonance Imaging (fMRI) to Detect and Characterize the Effects of Two Marketed Centrally Active Drugs, Placebo, and RO4917523 in Healthy Volunteers

Completed· Roche logo

Roche·Phase 1·NCT01045083·25 enrolled

Prophylaxis1 trial

Prophylaxis of Psychiatric Symptoms During Anti-HCV Treatment

Completed·FFoundation for Liver Research·Phase 2/3·NCT00133276·80 enrolled

Irritable Bowel Syndrome1 trial

Escitalopram Trial for Irritable Bowel Syndrome (IBS) Patients With Panic Disorder

Completed·MMaastricht University Medical Center·Phase 4·NCT01551225·32 enrolled

Total Knee Arthroplasty1 trial

Analgesic Effect of Escitalopram in Total Knee Arthroplasty (TKA)

Completed·HHvidovre University Hospital·Phase 4·NCT01430520·120 enrolled

Withdrawal Syndrome1 trial

Treatment of Marijuana Withdrawal Syndrome Using Escitalopram and Cognitive-Behavior Therapy

Unknown status·TTel-Aviv Sourasky Medical Center·N/A·NCT00598052·40 enrolled

Social Anxiety Disorder1 trial

Escitalopram in Patients With Social Anxiety Disorder

Completed· Lundbeck logo

Lundbeck·Phase 4·NCT00902226·30 enrolled

Conditioning1 trial

Influence of Escitalopram on Fear Conditioning

Completed·MMassachusetts General Hospital·Phase 4·NCT01398514·65 enrolled

Shock1 trial

The Effect of SSRIs on Threat of Shock Potentiated Neural Circuitry

Completed·UUCLH/UCL Joint Research Office·N/A·NCT07074652·145 enrolled

Effectiveness1 trial

Effectiveness of Escitalopram in the Treatment of Body Dysmorphic Disorder

Completed·MMassachusetts General Hospital·Phase 3·NCT00149799·100 enrolled

Age1 trial

Developing New Clinical Management Strategies

Completed·NNew York State Psychiatric Institute·Phase 4·NCT02082392·3 enrolled

Cocaine Dependence1 trial

Modafinil - Escitalopram Study for Cocaine Dependence

Completed·—·Phase 1·NCT01601730·68 enrolled

Low Birth Weight1 trial

Effects of 3 Months of Selective Serotonin Reuptake Inhibitor (SSRI)-Treatment on Metabolism and Hypothalamic-pituitary-adrenal (HPA)-Axis in Young Men Born With Low Birth Weight

Completed·UUniversity of Aarhus·N/A·NCT00971815·60 enrolled

Brain Aging1 trial

Brain Aging and Treatment Response in Geriatric Depression

Completed·UUniversity of California, Los Angeles·Phase 4·NCT01902004·115 enrolled

Function1 trial

Mechanism of Antidepressant-Related Dysfunctional Arousal in High-Risk Youth

Completed·UUniversity of Cincinnati·N/A·NCT02553161·214 enrolled

Pulmonary Hypertension1 trial

Serotonin Transporter Inhibitor Escitalopram in Pulmonary Hypertension

Completed·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT00190333·30 enrolled

Fatigue1 trial

A Trial Examining the Efficacy of Escitalopram Oxalate Upon Depressive Symptoms and Fatigue in HIV Seropositive Women

Terminated·—·Phase 4·NCT01797380·5 enrolled

Adolescent1 trial

Development and Application of Comprehensive Intervention Techniques for Adolescent Depression

Recruiting·FFirst Affiliated Hospital of Zhejiang University·N/A·NCT05945342·100 enrolled

Mechanical Ventilation1 trial

Preventing Depression in People Receiving Mechanical Ventilation in an Intensive Care Unit

Completed·UUniversity of Minnesota·Phase 4·NCT00872027·15 enrolled

Menopausal Symptoms1 trial

MsFLASH-01: Escitalopram for Menopausal Symptoms in Midlife Women

Completed·FFred Hutchinson Cancer Center·N/A·NCT00894543·205 enrolled

Randomized1 trial

Randomized, Double Blind, Efficacy Study of Escitalopram in ENT Cancer Patients Suffering From Emotional Distress

Completed·GGustave Roussy, Cancer Campus, Grand Paris·Phase 3·NCT02246244·38 enrolled

Platelet Function1 trial

Depression, Epinephrine, and Platelet Function

Completed·EEmory University·Phase 4·NCT00166114·40 enrolled

First-line Treatment1 trial

The Effect of a Six Week Intensified Pharmacological Treatment for Bipolar Depression Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment.

Recruiting·—·Phase 3·NCT05973786·418 enrolled

Brain Injury1 trial

Lexapro for the Treatment of Traumatic Brain Injury (TBI) Depression & Other Psychiatric Conditions

Completed·JJohns Hopkins University·Phase 2·NCT01368432·16 enrolled

AIN1 trial

Brain Effects of Escitalopram and Citalopram Using fMRI

Completed·—·Phase 4·NCT00825825·27 enrolled

Asthma1 trial

Escitalopram in Asthma Patients With Frequent Exacerbation

Recruiting·UUniversity of Texas Southwestern Medical Center·Phase 2·NCT06216535·105 enrolled

Aging1 trial

Leveraging EEG for Antidepressant Prediction With Sertraline and Escitalopram

Withdrawn·AAlto Neuroscience·Phase 4·NCT04388202

Postmenopausal Women1 trial

Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) vs. Escitalopram in Postmenopausal Women

Completed· Pfizer logo

Pfizer·Phase 3·NCT00406640·595 enrolled

Addiction1 trial

Clinical Neurobiology of Serotonin and Addiction

Completed·VVirginia Commonwealth University·Phase 2/3·NCT00732901·160 enrolled

Cognitive Dysfunction1 trial

Cognitive Dysfunction in MDD Patients

Unknown status·OOleg Levada·Phase 4·NCT03187093·150 enrolled

Genetic Polymorphism1 trial

Pharmacokinetic and Pharmacodynamic Effects of Escitalopram Depending on Genetic Polymorphisms of the ABCB1-gene

Completed·MMax-Planck-Institute of Psychiatry·N/A·NCT00550485·79 enrolled

Humans1 trial

The Role of Serotonin in Compulsive Behavior in Humans: Underlying Brain Mechanisms

Active, not recruiting·RRigshospitalet, Denmark·Phase 4·NCT04336228·46 enrolled

Memory1 trial

Memory Functioning and Antidepressant Treatment

Completed·UUniversity Health Network, Toronto·Phase 3·NCT00296933·60 enrolled

Single Dose1 trial

A PET Study to Determine Alterations in Serotonin Levels in Human Brain After a Single Dose of Escitalopram

Completed·KKarolinska Institutet·Phase 1·NCT01638689·10 enrolled

Parkinson's Disease1 trial

Antidepressants Trial in Parkinson's Disease

Completed·UUniversity College, London·Phase 3·NCT03652870·52 enrolled

Electroacupuncture1 trial

Effect of Electroacupuncture on Treating the First-episode Depression

Recruiting·SShanghai Municipal Hospital of Traditional Chinese Medicine·N/A·NCT05818735·204 enrolled

Pilot Study1 trial

Escitalopram for Premenstrual Syndrome (PMS) in Teens: A Pilot Study

Terminated·UUniversity of Pennsylvania·Phase 4·NCT00523705·11 enrolled

Unspecified7 trials

Serotonin and Motor Plasticity

Unknown status·MMax Planck Institute for Human Cognitive and Brain Sciences·Phase 4·NCT03162185·60 enrolled

Neural Responses and Dysphoria: Modulation by a Pharmacological Probe

Completed·UUniversity of Oxford·Phase 4·NCT01101685·160 enrolled

Development of Escitalopram Genomic Device by Using Candidate Gene Approach and Genome-Wide Scanning

Unknown status·SSamsung Medical Center·N/A·NCT00935246·202 enrolled

Show 4 more trials

EScitalopram PIndolol ONset of Action

Terminated·MMarkus KOSEL·Phase 2/3·NCT01219686·18 enrolled

Evaluation of the Effects of Duloxetine on Norepinephrine

Completed· Eli Lilly logo

Eli Lilly·Phase 1·NCT00414323·35 enrolled

Bupropion Versus Escitalopram on Reward Circuitry and Motivational Deficits

Completed·EEmory University·Phase 4·NCT04352101·18 enrolled

Bioequivalence Study of Escitalopram Tablets 10 mg

Completed· GSK logo

GSK·Phase 1·NCT01745601·26 enrolled

Regulatory

FDA Approval Timeline[5]

Aug 14, 2002

LEXAPRO

NDA NDA021323

Aug 29, 2002

LEXAPRO

NDA NDA021323

Nov 27, 2002

LEXAPRO

NDA NDA021365

Dec 13, 2002

LEXAPRO

NDA NDA021323

Dec 18, 2003

LEXAPRO

NDA NDA021323

Dec 18, 2003

LEXAPRO

NDA NDA021323

Apr 8, 2004

LEXAPRO

NDA NDA021323

May 20, 2004

LEXAPRO

NDA NDA021323

Jan 11, 2005

LEXAPRO

NDA NDA021323

Feb 18, 2005

LEXAPRO

NDA NDA021323

Aug 2, 2007

LEXAPRO

NDA NDA021323

Sep 18, 2008

LEXAPRO

NDA NDA021323

Oct 11, 2008

LEXAPRO

NDA NDA021323

Jan 30, 2009

LEXAPRO

NDA NDA021323

Mar 19, 2009

LEXAPRO

NDA NDA021323

Mar 19, 2009

LEXAPRO

NDA NDA021323

Mar 11, 2011

LEXAPRO

NDA NDA021323

May 12, 2011

LEXAPRO

NDA NDA021323

Dec 3, 2012

LEXAPRO

NDA NDA021323

Mar 7, 2013

LEXAPRO

NDA NDA021323

May 29, 2013

LEXAPRO

NDA NDA021323

Jul 8, 2014

LEXAPRO

NDA NDA021323

Oct 31, 2014

LEXAPRO

NDA NDA021323

Jan 28, 2016

LEXAPRO

NDA NDA021323

Jan 4, 2017

LEXAPRO

NDA NDA021323

Jan 11, 2019

LEXAPRO

NDA NDA021323

Aug 28, 2020

LEXAPRO

NDA NDA021323

Sep 20, 2021

LEXAPRO

NDA NDA021323

May 12, 2023

LEXAPRO

NDA NDA021323

Aug 18, 2023

LEXAPRO

NDA NDA021323

Apr 19, 2024

LEXAPRO

NDA NDA021323

Aug 29, 2025

ESCITALOPRAM

NDA NDA219130

Sources

References

[1]
ClinicalTrials.gov — 326 trial records for Escitalopram. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Lexapro drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Escitalopram compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Escitalopram. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA219130). U.S. Food & Drug Administration.
[6]
SEC EDGAR — AbbVie company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Serotonin Transporter Inhibitor[3]
Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: AbbVie